IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

被引：0

作者：

Eraslan, Lale Erdem ^{[1
]}

van den Bent, Martin ^{[1
]}

Kros, Johan ^{[1
]}

Oosterkamp, Hendrika ^{[2
]}

Walenkamp, Annemiek ^{[3
]}

Beerepoot, Laurens ^{[4
]}

Hanse, Monique ^{[5
]}

Buter, J. ^{[6
]}

Honkoop, Aafke ^{[7
]}

van der Holt, Bronno ^{[1
]}

Vernhout, R. M. ^{[1
]}

Smitt, Peter Sillevis ^{[1
]}

Taal, Walter ^{[1
]}

French, Pim ^{[1
]}

机构：

[1] Erasmus MC, Rotterdam, Netherlands

[2] MC Haaglanden, The Hague, Netherlands

[3] Univ Med Ctr Groningen, Groningen, Netherlands

[4] Elisabeth Hosp, Tilburg, Netherlands

[5] Catharina Hosp, Eindhoven, Netherlands

[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[7] Isala Klin, Zwolle, Netherlands

来源：

NEURO-ONCOLOGY | 2014年 / 16卷

关键词：

D O I：

10.1093/neuonc/nou256.10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

GE-10

引用

页数：1

共 50 条

[41] IDENTIFICATION OF PATIENTS THAT WILL NOT BENEFIT FROM HEPATIC RADIATION
Lock, Michael
Callan, Laura
Gaede, Stewart
Cao, Jeff
D'Souza, David
Rodrigues, George
Vickress, Jason
Wong, Eugene
RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S36 - S36
[42] EVALUATION OF CLINICAL BENEFIT IN PATIENTS TREATED WITH BEVACIZUMAB
Villani, V.
Fabi, A.
Lombardi, G.
Bellu, L.
Zagonel, V.
Carapella, C. M.
Sperduti, I.
Vidiri, A.
Pace, A.
NEURO-ONCOLOGY, 2016, 18 : 57 - 57
[43] Safety and efficacy of Tumor Treating Fields (TTFields) combined with bevacizumab and systemic chemotherapy in recurrent GBM
Kang, Xun
Cai, Zehao
Chen, Feng
Zhang, Botao
Jiang, Bo
Li, Wenbin
CANCER RESEARCH, 2023, 83 (08)
[44] CLINICAL PREDICTIVE FACTORS OF INCREASE OVERALL SURVIVAL WITH BEVACIZUMAB/IRINOTECAN FOR PRIMARY RECURRENT GLIOBLASTOMA (GBM)
Frenel, J. S.
Leux, C.
Tollec, S.
Martin, S.
Labbe, C.
Loussouarn, D.
Campone, M.
ANNALS OF ONCOLOGY, 2010, 21 : 330 - 330
[45] BEVACIZUMAB (BEV) ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN RECURRENT GLIOBLASTOMA MULTIFORME (GBM): A REAL WORLD EXPERIENCE
Chalchal, H. I.
Zhu, T.
Woitas, C.
Ahmed, S.
Souied, O.
Iqbal, M.
Ahmed, O.
Sami, A.
Dueck, D.
Magdi, A.
NEURO-ONCOLOGY, 2021, 23 : 52 - 52
[46] Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab
Liau, Chi-Ting
Chou, Wen-Chi
Wei, Kuo-Chen
Chang, Chen-Nen
Toh, Cheng-Hong
Jung, Shih-Ming
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (02) : E8 - E14
[47] BEVACIZUMAB ADMINISTRATION TO GBM PATIENTS INCREASES TIME SPENT LIVING INDEPENDENTLY
Recht, Seema Nagpal Lawrence
NEURO-ONCOLOGY, 2010, 12 : 103 - 103
[48] Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Bond, Marinde J. G.
van Smeden, Maarten
Degeling, Koen
Cremolini, Chiara
Schmoll, Hans-Joachim
Antoniotti, Carlotta
Lonardi, Sara
Murgioni, Sabina
Rossini, Daniele
Ibach, Stefan
Koopman, Miriam
Swijnenburg, Rutger-Jan
Punt, Cornelis J. A.
May, Anne M.
Kwakman, Johannes J. M.
JCO CLINICAL CANCER INFORMATICS, 2024, 8
[49] Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Bond, Marinde J. G.
van Smeden, Maarten
Degeling, Koen
Cremolini, Chiara
Schmoll, Hans-Joachim
Antoniotti, Carlotta
Lonardi, Sara
Murgioni, Sabina
Rossini, Daniele
Ibach, Stefan
Koopman, Miriam
Swijnenburg, Rutger-Jan
Punt, Cornelis J. A.
May, Anne M.
Kwakman, Johannes J. M.
JCO CLINICAL CANCER INFORMATICS, 2024, 8
[50] Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy
Seol, Aeran
Yim, Ga Won
Chung, Joo Yeon
Kim, Se Ik
Lee, Maria
Kim, Hee Seung
Chung, Hyun Hoon
Kim, Jae-Weon
Park, Noh Hyun
Song, Yong Sang
CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1219 - 1229

← 1 2 3 4 5 →